Program Overview
This CME activity is derived from content presented at the Digestive Disease Week (DDW) 2021 Virtual Meeting. The expert faculty will highlight sphingosine-1-phosphate (S1P) therapeutics to improve outcomes for patients with moderate to severe ulcerative colitis (UC). Additionally, a review of S1P receptor modulators as a therapeutic target to support the management of ulcerative colitis will be discussed. The faculty will then analyze clinical trial data for the safety and efficacy of novel S1P therapeutics to treat patients with UC. Following, a review of best practices for developing treatment strategies for patients with moderate to severe ulcerative colitis will be explored. The faculty will conclude with an interactive panel discussion, delving into sphingosine-1-phosphate receptor modulator science as a therapeutic target to improve outcomes in patients with ulcerative colitis.
Target Audience
Gastroenterologists and other healthcare professionals who care for patients with ulcerative colitis
Learning Objectives
- Understand the sphingosine-1-phosphate (S1P) receptor modulator as a therapeutic target to support the management of ulcerative colitis.
- Analyze recently completed and ongoing clinical trials for the efficacy and safety of novel S1P therapeutics to treat patients with moderate to severe ulcerative colitis.
- Develop treatment strategies for the application of novel therapeutics to treat patients with moderate to severe ulcerative colitis.
Agenda
I. Scientific Update for Sphingosine-1-Phosphate (S1P) Receptor Modulators as a Therapeutic Target for Ulcerative Colitis – William J. Sandborn, MD
II. A Clinical Trial Review and Analysis on the Safety and Efficacy of Novel S1P Therapeutics for the Management of Moderate to Severe Ulcerative Colitis Disease – David T. Rubin, MD
III. Treatment Strategies to Apply Novel Therapeutics to Optimize Patient Outcomes – Miguel Regueiro, MD
IV. Interactive Panel Discussion –All Faculty
Chair
William J. Sandborn, MD
Professor of Medicine
Division of Gastroenterology
University of California, San Diego
San Diego, CA
Faculty
Miguel Regueiro, MD
Professor of Medicine
Lerner College of Medicine
Chair, Department of Gastroenterology, Hepatology & Nutrition
Vice Chair, Digestive Diseases and Surgery Institute
Cleveland Clinic
Cleveland, OH
David T. Rubin, MD
Joseph B. Kirsner Professor of Medicine
Chief, Section of Gastroenterology, Hepatology and Nutrition
University of Chicago
Chicago, IL
Disclosures of Conflict of Interest
It is the policy of AcademicCME that all faculty, instructors, and planners disclose real or apparent conflicts of interest relating to the topics of this educational activity.
The faculty reported the following financial relationships or relationships to products or devices they or their spouse/life partner have with commercial interests related to the content of this CE activity:
| Faculty | Relationship Identified With: |
| William J. Sandborn, MD
|
Consultant/Advisor: AbbVie Inc.; ABIVAX; Admirx; Alfasigma USA, Inc.; Alimentiv; Alivio Therapeutics; Allakos Inc.; Amgen Inc.; Applied Molecular Transpor Inc.; Arena Pharmaceuticals, Inc.; Bausch Health Companies Inc.; BeiGene; Bellatrix Pharmaceuticals; Boehringer Ingelheim; Boston Pharmaceuticals; Bristol Meyers Squibb; Celgene; Celltrion Healthcare Co.,Ltd.; Celularity Inc.; Cosmo Pharmaceuticals; Eli Lilly and Company; Escalier Biosciences; Equillium, Inc.; Forbion Capital Partners; Genentech USA, Inc.; Gilead Sciences, Inc.; Glenmark Pharmaceuticals, Inc.; Gossamer Bio; Immunic Therapeutics; InDex Pharmaceuticals; Intact Therapeutics, Inc; Janssen Pharmaceuticals, Inc.; Kyverna Therapeutics, Inc.; Landos Biopharma, Inc.; Oppilan Pharma Ltd.; Otsuka America Pharmaceutical, Inc.; Pandion Therapeutics; Pfizer Inc.; Progenity, Inc; Prometheus Biosciences; Protagonist Therapeutics; ProventionBio; Reistone Biopharma; Seres Therapeutics, Shanghai Pharma Biotherapeutics, Shire, Shoreline Biosciences, Sublimity Therapeutics; Surrozen; Takeda Pharmaceutical Company; Theravance Biopharma; Thetis Pharmaceuticals LLC; Tillotts Pharma AG; UCB; Vedanta Biosciences, Inc.; Ventyx Biosciences, Inc.; Vimalan Biosciences, Inc.; Vivelix Pharmaceuticals; Vivreon Biosciences; Zealand Pharma
Grant/Research Support: AbbVie Inc.; ABIVAX; Arena Pharmaceuticals, Inc.; Boehringer Ingelheim; Celgene; Eli Lilly and Company; Genentech USA, Inc.; Gilead Sciences, Inc.; GlaxoSmithKline; Janssen Pharmaceuticals, Inc.; Pfizer Inc.; Prometheus Biosciences; Seres Therapeutics; Shire LLC; Takeda Pharmaceutical Company; Theravance Biopharma, Inc. Stocks: Allakos Inc.; BeiGene, Gossamer Bio; Oppilan Pharma Ltd; Prometheus Biosciences; Progenity; Shoreline Biosciences, Inc.; Ventyx Biosciences, Inc.; Vimalan Biosciences, Inc. |
| Miguel Regueiro, MD | Consultant/Advisor: AbbVie Inc.; Allergan; Amgen Inc.; Arena Pharmaceuticals, Inc.; Bristol Meyers Squibb; Eli Lilly and Company; Genentech USA, Inc; Gilead Sciences, Inc.; Janssen Pharmaceuticals, Inc.; Pfizer Inc.; Prometheus Biosciences; Salix Pharmaceuticals; Seres Therapeutics; Takeda Pharmaceutical Company; UCB
Grant/Research Support: AbbVie Inc.; Janssen Pharmaceuticals, Inc.; Pfizer Inc.; Takeda Pharmaceutical Company |
| David T. Rubin, MD | Consultant/Advisor: AbbVie Inc.; Altrubio; Allergan; Arena; Athos Therapeutics; Bellatrix Pharmaceuticals; Boehringer Ingelheim; Bristol Meyers Squibb; Celgene Corp/Syneos; GalenPharma/Atlantica; Genentech USA, Inc.; Gilead Sciences, Inc.; InDex Pharmaceuticals; Ironwood Pharmaceuticals; Iterative Scopes; Janssen Pharmaceuticals, Inc.; Lilly; Materia Prima; Pfizer Inc.; Prometheus Biosciences; Reistone Biopharma; Takeda Pharmaceutical Company; Techlab, Inc. |
Planners and Peer Reviewers
Timothy Hayes, MD, PhD; Kim Cheramie, MSN, RN-BC; Chelsey Benedek and Nicole McMenamin hereby state that they or their spouse/life partner do not have any financial relationships to products or devices with any commercial interests related to the content of this activity of any amount during the past 12 months.
Accreditation Statement
In support of improving patient care, AcademicCME is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.
Credit Designation Statements
AcademicCME designates this enduring material for a maximum of 1.5 AMA PRA Category 1 CreditsTM.
Physcians should claim only the credit commensurate with the extent of their participation in the activity.
Financial Support
This activity has been supported by an independent educational grant from Bristol Myers Squibb
Disclosure of Unlabeled Use
This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. AcademicCME and Bristol Myers Squibb do not recommend the use of any agent outside of the labeled indications.
Disclaimer
Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications on dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.
Method of Participation
In order to claim credit, participants must complete the following:
- Read the learning objectives, accreditation information and faculty disclosures at the beginning of this activity.
- Complete the Pre-Activity Questions
- Read or Review the activity content.
- Complete the Post-Activity Test Questions and Evaluation.
- Learners who receive a grade of 70% or better on the Post-Activity Test Questions and complete the Evaluation will receive appropriate credit as indicated (CME, CNE, and/or CPE credit).
- CPE credit will be posted to the learner’s CPE Monitor profile within 60 days of completion.
- CME and CNE credit will be issued appropriate certificate of completion.
- Others may request a “certificate of completion”.
- Learners should claim only the credit commensurate with the extent of their participation in the activity.
CE Inquiries/Special Needs
For all CE inquiries or special needs, please contact [email protected].
